KalVista Pharmaceuticals (KALV) Interest Coverage Ratio (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Interest Coverage Ratio of 16.75 for Q3 2025, down 188.33% on a YoY basis from 18.97 in Q3 2024, and down 152.35% sequentially from 6.64 in Q4 2024.
KalVista Pharmaceuticals (KALV) Interest Coverage Ratio (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Interest Coverage Ratio data on file, last reported at 16.75 in Q3 2025.
- For the quarter ending Q3 2025, Interest Coverage Ratio fell 188.33% year-over-year to 16.75; the trailing twelve-month figure through Jul 2025 stood at 52.73 (down 157.91% YoY), and the FY2025 full-year result was 2.89, up 94.84% from the prior year.
- Interest Coverage Ratio fell to 16.75 in Q3 2025, from 6.64 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.95 in Q2 2022 to a low of 69.13 in Q2 2021.
- A 5-year average of 11.51 and a median of 3.33 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio tumbled 422.16% in 2021 and surged 98.63% in 2022, its largest moves.
- Tracing KALV's Interest Coverage Ratio over 5 years: stood at 2.5 in 2021, then grew by 9.04% to 2.27 in 2022, then slumped by 35.41% to 3.08 in 2023, then sank by 115.83% to 6.64 in 2024, then tumbled by 152.35% to 16.75 in 2025.
- Business Quant data shows KALV's Interest Coverage Ratio at 16.75 in Q3 2025, 6.64 in Q4 2024, and 5.81 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -16.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -16.75 |
| Oct 31, 2024 | -6.64 |
| Jul 31, 2024 | -5.81 |
| Apr 30, 2024 | -19.34 |
| Jan 31, 2024 | -3.58 |
| Oct 31, 2023 | -3.08 |
| Jul 31, 2023 | -2.87 |
| Jan 31, 2023 | -2.42 |
| Oct 31, 2022 | -2.27 |
| Jul 31, 2022 | -2.21 |
| Apr 30, 2022 | -0.95 |
| Jan 31, 2022 | -2.33 |
| Oct 31, 2021 | -2.50 |
| Jul 31, 2021 | -7.97 |
| Apr 30, 2021 | -69.13 |
| Jan 31, 2021 | -36.27 |
| Oct 31, 2020 | -38.15 |
| Jul 31, 2020 | -43.63 |
| Apr 30, 2020 | -51.77 |
| Jan 31, 2020 | -6.95 |